Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Biosafety of recombinant adeno-associated virus vectors.

Dismuke DJ, Tenenbaum L, Samulski RJ.

Curr Gene Ther. 2013 Dec;13(6):434-52. Review.

PMID:
24195602
2.

Hepatic gene therapy using lentiviral vectors: has safety been established?

Dismuke D, Samulski RJ.

Hepatology. 2013 Jul;58(1):13-4. doi: 10.1002/hep.26460. No abstract available.

PMID:
23695955
3.

Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release.

Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MR, Griffith JD, Harvey SC, Asokan A.

J Virol. 2013 Mar;87(6):2994-3002. doi: 10.1128/JVI.03017-12. Epub 2012 Dec 26.

4.

Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP.

Gene Ther. 2012 Oct;19(10):999-1009. doi: 10.1038/gt.2011.169. Epub 2011 Nov 10.

PMID:
22071974
6.

Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.

Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH.

J Virol. 2004 Jan;78(2):922-9.

Supplemental Content

Loading ...
Support Center